Intended Use

The DermaSensor device is indicated for use to evaluate skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients aged 40 and above to assist in the decision regarding referral of the patient to a dermatologist.

Technology

The device consists of a handheld unit with a broadband light source and fiber-optic probe that transmits white light to the skin lesion and collects backscattered light, which is spectrally analyzed by a microspectrometer. A proprietary ML-derived classifier algorithm analyzes the spectral pattern via an internal microprocessor and returns a binary classification output at point of care.

Performance

Clinical performance testing including a pivotal multicenter study with 1,005 patients and 1,579 lesions demonstrated overall sensitivity of 95.5% for melanoma, SCC, and BCC, superior to primary care physicians. Specificity was lower (20.7%) but clinically acceptable. Multiple reader studies showed improved physician sensitivity with device aid. Non-clinical bench tests confirmed device safety, repeatability, biocompatibility, and software validation. Post-market surveillance is required for further validation especially in diverse skin phototypes.

Ready to Sharpen Your Edge?

Subscribe to join 7,600+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.